Clinical Trial Update: Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating SB623-modified stem cells for chronic motor deficit due to ischemic stroke has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• SB623-modified stem cells

Snippet

Sponsor: SanBio, Inc. | Conditions: Chronic Ischemic Stroke | Phase 2 | Status: COMPLETED | Results posted: 2020-04-17